|
MechanismBacterial DNA gyrase inhibitors [+1] |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.CN |
First Approval Date01 Jan 1992 |
A randomized parallel-group comparative study to verify efficacy (non-inferiority) of BLR250 using Dianeal PD-4 as a comparator in patients with chronic renal failure receiving CAPD (Continuous Ambulatory Peritoneal Dialysis)
A randomized parallel-group comparative study to verify efficacy (non-inferiority) of BLR350 using Dianeal PD-2 as a comparator in patients with chronic renal failure receiving CAPD (Continuous Ambulatory Peritoneal Dialysis)
Identification of Early Biomarkers of Peritoneal Membrane Dysfunction in Children on Peritoneal Dialysis Using Metabolomics Analysis
Ability and sensitivity of metabolomics analysis to highlight biomarkers or a score of biomarkers that will be able to identify those pediatric patients on peritoneal dialysis at high risk for possible peritoneal dialysis complications and mainly encapsulating peritoneal sclerosis
100 Clinical Results associated with Baxter Co. Ltd.
0 Patents (Medical) associated with Baxter Co. Ltd.
100 Deals associated with Baxter Co. Ltd.
100 Translational Medicine associated with Baxter Co. Ltd.